Search
DEEN
more info

Contact:
Phone:+49 0761 1514 440Fax:+49 0761 1514 460Email:info[at]falkfoundation.org

    Falk Gastro Review Journal

    Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

    Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

    The latest issues

    Edition 4/2024

    read more

    Edition 3/2024

    read more

    Edition 2/2024

    read more

    Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

    All articles

    Liver and Bile

    Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomized, double-blind, placebo-controlled, phase 3 trial

    Lancet. 2023;401(10391):1853–65

    Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators

    Go to article

    Liver and Bile

    Gallstones, cholecystectomy, and kidney cancer: Observational and Mendelian randomization results based on large cohorts

    Gastroenterology. 2023;165(1):218–27.e8

    Kharazmi E, Scherer D, Boekstegers F, Liang Q, Sundquist K, Sundquist J, Fallah M, Lorenzo Bermejo J

    Go to article

    Liver and Bile

    Risk of parenterally transmitted hepatitis following exposure to invasive procedures in Italy: SEIEVA surveillance 2000–2021

    J Hepatol. 2023;79(1):61–68

    Caminada S, Mele A, Ferrigno L, Alfonsi V, Crateri S, Iantosca G, Sabato M, Tosti ME; SEIEVA Collaborating Group

    Go to article

    Liver and Bile

    Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma

    J Gastroenterol Hepatol. 2023;38(6):976–83

    Mnatzaganian G, MacLachlan JH, Allard N, Brown C, Rowe S, Cowie BC

    Go to article

    Liver and Bile

    Differential relapse patterns after discontinuation of entecavir vs. tenofovir disoproxil fumarate in chronic hepatitis B

    Clin Gastroenterol Hepatol. 2023;21(6):1513–22.e4

    Choi HSJ, Hirode G, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong GLH, Brakenhoff SM, Chien RN, Feld JJ, Sonneveld MJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA; RETRACT-B study group

    Go to article

    Liver and Bile

    Posttreatment HBsAg decline predicts high rate of HBsAg loss after stopping entecavir or tenofovir in HBeAg-negative patients without retreatment

    Dig Liver Dis. 2023;55(9):1223–9

    Fang HW, Hu TH, Wang JH, Hung CH, Lu SN, Chen CH

    Go to article

    Liver and Bile

    A phase 3, randomized trial of bulevirtide in chronic hepatitis D

    N Engl J Med. 2023;389(1):22–32

    Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Manuilov D, Suri V, An Q, Da B, Flaherty J, Osinusi A, Liu Y, Merle U, Schulze zur Wiesch J, Zeuzem S, Ciesek S, Cornberg M, Lampertico P; MYR 301 Study Group

    Go to article

    Liver and Bile

    No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase 2 and 3 clinical trials for chronic hepatitis delta

    J Hepatol. 2023;79(3):657–65

    Hollnberger J, Liu Y, Xu S, Chang S, Martin R, Manhas S, Aeschbacher T, Han B, Yazdi T, May L, Han D, Shornikov A, Flaherty J, Manuilov D, Suri V, Asselah T, Lampertico P, Wedemeyer H, Aleman S, Richards C, Mateo R, Maiorova E, Cihlar T, Mo H, Urban S

    Go to article

    Liver and Bile

    Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)

    Hepatology. 2023;78(1):272–83

    Nabi O, Lapidus N, Boursier J, de Ledinghen V, Petit JM, Kab S, Renuy A, Zins M, Lacombe K, Serfaty L

    Go to article